The 𝐆𝐫𝐚𝐳𝐨𝐩𝐫𝐞𝐯𝐢𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 has evolved since it was first approved for the treatment of chronic hepatitis C virus (HCV) infection in 2016. Initially, grazoprevir was launched as a combination therapy with elbasvir under the brand name Zepatier, and it was positioned as an alternative treatment option for HCV genotype 1 and 4 infections. However, since …